Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.

Zev A. Wainberg; Saeed Rafii; Ramesh K. Ramanathan; Lida A. Mina; Lauren Averett Byers; Rashmi Chugh; Jonathan Wade Goldman; Jasgit C. Sachdev; Daniela E. Matei; Jennifer J. Wheler; Joshua W. Henshaw; Charlie Zhang; Gilles Gallant; Johann Sebastian De Bono

doi:10.1200/jco.2014.32.15_suppl.7522

Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7522 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7522-7522 ◽

Cited By ~ 22

Author(s):

Zev A. Wainberg ◽

Saeed Rafii ◽

Ramesh K. Ramanathan ◽

Lida A. Mina ◽

Lauren Averett Byers ◽

...

Keyword(s):

Lung Cancer ◽

Antitumor Activity ◽

Cancer Patients ◽

Brca Mutation ◽

Phase 1 ◽

Parp Inhibitor ◽

Small Cell ◽

Brca Mutation Carrier ◽

Small Cell Lung ◽

Germline Brca Mutation

Download Full-text

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

Lung Cancer ◽

10.1016/j.lungcan.2020.10.003 ◽

2020 ◽

Vol 150 ◽

pp. 90-96 ◽

Cited By ~ 1

Author(s):

Vivek Subbiah ◽

Luis Paz-Ares ◽

Benjamin Besse ◽

Victor Moreno ◽

Solange Peters ◽

...

Keyword(s):

Lung Cancer ◽

Antitumor Activity ◽

Cancer Patients ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

First Line ◽

Lung Cancer Patients ◽

First Line Treatment

Download Full-text

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Cancer Immunology Immunotherapy ◽

10.1007/s00262-014-1547-6 ◽

2014 ◽

Vol 63 (8) ◽

pp. 787-796 ◽

Cited By ~ 29

Author(s):

David A. Smith ◽

Paul Conkling ◽

Donald A. Richards ◽

John J. Nemunaitis ◽

Thomas E. Boyd ◽

...

Keyword(s):

Lung Cancer ◽

Antitumor Activity ◽

Combination Therapy ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Small Cell ◽

Toll Like Receptor ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients

Journal of Thoracic Oncology ◽

10.1097/01243894-200607000-00004 ◽

2006 ◽

Vol 1 (6) ◽

pp. 520-525 ◽

Cited By ~ 16

Author(s):

Gee-Chen Chang ◽

Chun-Ming Tsai ◽

Kun-Chieh Chen ◽

Chong-Jen Yu ◽

Jin-Yuan Shih ◽

...

Keyword(s):

Lung Cancer ◽

Antitumor Activity ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Predictive Factors ◽

Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

Abstract 5444: Modulation of ErbB receptors expression by histone deacetylase inhibitors increased the antitumor activity of an anti-ErbB3 monoclonal antibody in primary cultures from non-small cell lung cancer patients

10.1158/1538-7445.am2014-5444 ◽

2014 ◽

Author(s):

Chiara Ciardiello ◽

Alessandra Leone ◽

Francesca Bruzzese ◽

Maria Serena Roca ◽

Alessia Noto ◽

...

Keyword(s):

Lung Cancer ◽

Monoclonal Antibody ◽

Antitumor Activity ◽

Cancer Patients ◽

Histone Deacetylase Inhibitors ◽

Primary Cultures ◽

Small Cell ◽

Erbb Receptors ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21057 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21057-e21057

Author(s):

Victor Moreno Garcia ◽

Emiliano Calvo ◽

Maria Eugenia Olmedo Garcia ◽

Marta Gil Martin ◽

Raid Aljumaily ◽

...

Keyword(s):

Lung Cancer ◽

Antitumor Activity ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Dose Escalation ◽

Phase 1 ◽

Small Cell ◽

Small Cell Lung ◽

Expansion Cohort

Download Full-text

Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(15)30353-1 ◽

2006 ◽

Vol 1 (6) ◽

pp. 520-525 ◽

Cited By ~ 11

Author(s):

Gee-Chen Chang ◽

Chun-Ming Tsai ◽

Kun-Chieh Chen ◽

Chong-Jen Yu ◽

Jin-Yuan Shih ◽

...

Keyword(s):

Lung Cancer ◽

Antitumor Activity ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Predictive Factors ◽

Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease

Clinical Lung Cancer ◽

10.1016/j.cllc.2016.09.002 ◽

2017 ◽

Vol 18 (1) ◽

pp. 68-76.e2 ◽

Cited By ~ 30

Author(s):

Mark A. Socinski ◽

Frederic J. Kaye ◽

David R. Spigel ◽

Fred J. Kudrik ◽

Santiago Ponce ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Phase 1 ◽

Small Cell ◽

Small Cell Lung ◽

Antibody Drug Conjugate ◽

Lung Cancer Patients ◽

Stage Disease ◽

Extensive Stage ◽

Antibody Drug

Download Full-text

A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7523 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7523-7523 ◽

Cited By ~ 1

Author(s):

Taofeek Kunle Owonikoko ◽

Suzanne Eleanor Dahlberg ◽

Saad A. Khan ◽

David E. Gerber ◽

Jonathan Dowell ◽

...

Keyword(s):

Lung Cancer ◽

Phase 1 ◽

Parp Inhibitor ◽

Eastern Cooperative Oncology Group ◽

Small Cell ◽

Oncology Group ◽

Small Cell Lung ◽

Phase 1 Study ◽

Oncology Group Study ◽

Extensive Stage

Download Full-text

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9050 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9050-9050 ◽

Cited By ~ 13

Author(s):

Helena Alexandra Yu ◽

Alexander I. Spira ◽

Leora Horn ◽

Jared Weiss ◽

Howard Jack West ◽

...

Keyword(s):

Lung Cancer ◽

Antitumor Activity ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Phase 1 ◽

Small Cell ◽

Small Cell Lung ◽

Phase 1 Study ◽

Ongoing Phase

Download Full-text

Safety of alectinib in non-small cell lung cancer patients with RET fusion gene (ALL-RET): Results from the dose-finding portion of a phase 1/2 study

Annals of Oncology ◽

10.1093/annonc/mdx671.008 ◽

2017 ◽

Vol 28 ◽

pp. x127 ◽

Cited By ~ 2

Author(s):

K. Nosaki ◽

S. Takeuchi ◽

S. Takahara ◽

T. Kawakami ◽

K. Yoh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Fusion Gene ◽

Phase 1 ◽

Small Cell ◽

Dose Finding ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text